ZLY18

ZLY18
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name 2-[2-Fluoro-4-[[3-methoxy-5-[(1E)-2-(4-methoxyphenyl)ethenyl]phenoxy]methyl]phenoxy]acetic acid;
CAS Number	2642392-33-2;
Chemical and physical data
Formula	C25H23FO6
Molar mass	438.451 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COc1ccc(cc1)C=Cc2cc(OC)cc(c2)OCc3ccc(c(F)c3)OCC(=O)O;
	InChI InChI=1S/C25H23FO6/c1-29-20-8-5-17(6-9-20)3-4-18-11-21(30-2)14-22(12-18)31-15-19-7-10-24(23(26)13-19)32-16-25(27)28/h3-14H,15-16H2,1-2H3,(H,27,28)/b4-3+; Key:QASIQJGISCBDLW-ONEGZZNKSA-N;

ZLY18 is an experimental drug that acts as an agonist of the free fatty acid receptor 1 (FFA1) and all three types of peroxisome proliferator-activated receptor (alpha, delta, and gamma). It is in development for the treatment of non-alcoholic fatty liver disease.^[1]^[2]^[3]^[4]

References[edit]

^ Zhou, Zongtao; Ren, Qiang; Jiao, Shixuan; Cai, Zongyu; Geng, Xinqian; Deng, Liming; Wang, Bin; Hu, Lijun; Zhang, Luyong; Yang, Ying; Li, Zheng (5 February 2022). "Discovery of new and highly effective quadruple FFA1 and PPARα/γ/δ agonists as potential anti-fatty liver agents". European Journal of Medicinal Chemistry. 229: 114061. doi:10.1016/j.ejmech.2021.114061. ISSN 1768-3254. PMID 34954593. S2CID 245394392.
^ Xu, Xiaohan; Poulsen, Kyle L.; Wu, Lijuan; Liu, Shan; Miyata, Tatsunori; Song, Qiaoling; Wei, Qingda; Zhao, Chenyang; Lin, Chunhua; Yang, Jinbo (2022). "Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)". Signal Transduction and Targeted Therapy. 7 (1): 287. doi:10.1038/s41392-022-01119-3. ISSN 2059-3635. PMC 9376100. PMID 35963848.
^ Gong, Lijun; Wei, Fang; Gonzalez, Frank J.; Li, Guolin (2023). "Hepatic fibrosis: Targeting peroxisome proliferator-activated receptor alpha from mechanism to medicines". Hepatology. 78 (5): 1625–1653. doi:10.1097/HEP.0000000000000182. PMC 10681123. PMID 36626642. S2CID 255593877.
^ Statham, Laura; Pelling, Melina; Hanson, Petra; Kyrou, Ioannis; Randeva, Harpal; Barber, Thomas M (4 May 2023). "Designer GLP1 poly-agonist peptides in the management of diabesity". Expert Review of Endocrinology & Metabolism. 18 (3): 231–240. doi:10.1080/17446651.2023.2204976. PMID 37089108. S2CID 258268432.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.